What's Topical? Devices for Transdermal Drug Delivery
Executive Summary
The drug delivery device industry is on track to reach almost $23 billion by the year 2011, and the fastest growth will come from the transdermal sector. According to a recent Windhover Information/Medtech Insight report, transdermal delivery technologies will build up to sales of $4.6 billion by 2011. Pharma's increasing fondness for macromolecules will fuel that growth, as will the perennially hot market for transdermal formulations of pain drugs.
You may also be interested in...
Macromolecules & Spec Pharma: The Good News in Drug Delivery
Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.
Drug Delivery Heats Up
The prices of drug-delivery deals have been going up -- thanks to spec pharma which has now turned almost entirely to the products of drug delivery and reformulation to re-stock their pipelines. Meanwhile, Big Pharma remains a minor player in small-molecule reformulation, but is increasingly active when it comes to macromolecules.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.